Cochlear (CHEOF) Stock Forecast & Price Target

Compare

30 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CHEOF Analyst Ratings

Hold

4 Buy

6 Hold

2 Sell

Based on 12 analysts giving stock ratings to

Cochlear

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CHEOF Stock 12 Month Forecast

Average Price Target

$207.10

▲(3.91% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Cochlear in the last 3 months. The average price target is $207.10 with a high forecast of $233.18 and a low forecast of $182.42. The average price target represents a 3.91% change from the last price of $199.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"164":"$164","199":"$199","234":"$234","181.5":"$181.5","216.5":"$216.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":233.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$233.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":207.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$207.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":182.42405,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$182.42</span>\n  </div></div>","useHTML":true}}],"tickPositions":[164,181.5,199,216.5,234],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,198.31,200.9923076923077,203.67461538461538,206.35692307692307,209.03923076923078,211.72153846153847,214.40384615384616,217.08615384615385,219.76846153846154,222.45076923076923,225.13307692307694,227.81538461538463,230.49769230769232,{"y":233.18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,198.31,198.98615384615385,199.6623076923077,200.33846153846153,201.01461538461538,201.69076923076923,202.3669230769231,203.0430769230769,203.71923076923076,204.39538461538461,205.07153846153847,205.7476923076923,206.42384615384614,{"y":207.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,198.31,197.08800384615384,195.8660076923077,194.64401153846154,193.42201538461538,192.20001923076924,190.97802307692308,189.75602692307692,188.53403076923075,187.31203461538462,186.09003846153846,184.8680423076923,183.64604615384616,{"y":182.42405,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":211.09,"date":1719792000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":216.57,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":207.17,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":186.5,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":179.57,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.02,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":200.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.31,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$233.18

Average Price Target$207.10

Lowest Price Target$182.42

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lila Implantra

TR | OpenAI - 4o

$214.19

Hold

7.47%

Upside

Reiterated

09/02/25

AI Generated ArticleAI Generated Article

David Bailey

Morgan Stanley

$179.47→$183.4

Sell

-7.98%

Downside

Reiterated

08/18/25

Morgan Stanley Remains a Sell on Cochlear (CHEOF)

Shane Storey

Wilsons

$216.15

Hold

8.45%

Upside

Reiterated

08/18/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ceribell, Inc. (NASDAQ: CBLL) and Cochlear (Other OTC: CHEOF)

David Low

J.P. Morgan

$199.78→$227.94

Buy

14.37%

Upside

Reiterated

08/18/25

J.P. Morgan Remains a Buy on Cochlear (CHEOF)

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$193.23

Hold

-3.05%

Downside

Reiterated

08/18/25

Ord Minnett Reaffirms Their Hold Rating on Cochlear (CHEOF)

Unknown Analyst

Macquarie

Not Ranked

Macquarie

$177.18→$193.81

Hold

-2.75%

Downside

Reiterated

08/18/25

Macquarie Reaffirms Their Hold Rating on Cochlear (CHEOF)

Derek Jellinek

Morgans

$184.29→$196.2

Sell

-1.56%

Downside

Downgraded

08/17/25

Cochlear (CHEOF) was downgraded to a Sell Rating at Morgans

Mathieu Chevrier

Citi

$229.25

Buy

15.03%

Upside

Reiterated

08/17/25

Citi Sticks to Their Buy Rating for Cochlear (CHEOF)

David Stanton

Jefferies

$231.87→$233.18

Buy

17.00%

Upside

Reiterated

08/15/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cullinan Management (NASDAQ: CGEM), Recursion Pharmaceuticals (NASDAQ: RXRX) and Cochlear (Other OTC: CHEOF)

Steven Wheen

Jarden

$177.03→$182.42

Hold

-8.47%

Downside

Reiterated

08/15/25

Jarden Keeps Their Hold Rating on Cochlear (CHEOF)

Craig Wong-Pan

RBC Capital

$192.57→$193.23

Hold

-3.05%

Downside

Reiterated

08/15/25

RBC Capital Reaffirms Their Hold Rating on Cochlear (CHEOF)

Marcus Curley

UBS

$212.88→$229.25

Buy

15.03%

Upside

Reiterated

08/15/25

UBS Sticks to Their Buy Rating for Cochlear (CHEOF)

Unknown Analyst

Macquarie

Not Ranked

Macquarie

$177.9→$177.18

Hold

-11.10%

Downside

Reiterated

07/16/25

Cochlear (CHEOF) Receives a Hold from Macquarie

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$186.68→$193.23

Hold

-3.05%

Downside

Reiterated

07/09/25

Cochlear (CHEOF) Receives a Hold from Ord Minnett

Davinthra Thillainathan

Goldman Sachs

―

Hold

―

Reiterated

06/14/25

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (NASDAQ: TNDM) and Cochlear (Other OTC: CHEOF)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lila Implantra

TR | OpenAI - 4o

$214.19

Hold

7.47%

Upside

Reiterated

09/02/25

AI Generated ArticleAI Generated Article

David Bailey

Morgan Stanley

$179.47→$183.4

Sell

-7.98%

Downside

Reiterated

08/18/25

Morgan Stanley Remains a Sell on Cochlear (CHEOF)

Shane Storey

Wilsons

$216.15

Hold

8.45%

Upside

Reiterated

08/18/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ceribell, Inc. (NASDAQ: CBLL) and Cochlear (Other OTC: CHEOF)

David Low

J.P. Morgan

$199.78→$227.94

Buy

14.37%

Upside

Reiterated

08/18/25

J.P. Morgan Remains a Buy on Cochlear (CHEOF)

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$193.23

Hold

-3.05%

Downside

Reiterated

08/18/25

Ord Minnett Reaffirms Their Hold Rating on Cochlear (CHEOF)

Unknown Analyst

Macquarie

Not Ranked

Macquarie

$177.18→$193.81

Hold

-2.75%

Downside

Reiterated

08/18/25

Macquarie Reaffirms Their Hold Rating on Cochlear (CHEOF)

Derek Jellinek

Morgans

$184.29→$196.2

Sell

-1.56%

Downside

Downgraded

08/17/25

Cochlear (CHEOF) was downgraded to a Sell Rating at Morgans

Mathieu Chevrier

Citi

$229.25

Buy

15.03%

Upside

Reiterated

08/17/25

Citi Sticks to Their Buy Rating for Cochlear (CHEOF)

David Stanton

Jefferies

$231.87→$233.18

Buy

17.00%

Upside

Reiterated

08/15/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cullinan Management (NASDAQ: CGEM), Recursion Pharmaceuticals (NASDAQ: RXRX) and Cochlear (Other OTC: CHEOF)

Steven Wheen

Jarden

$177.03→$182.42

Hold

-8.47%

Downside

Reiterated

08/15/25

Jarden Keeps Their Hold Rating on Cochlear (CHEOF)

Craig Wong-Pan

RBC Capital

$192.57→$193.23

Hold

-3.05%

Downside

Reiterated

08/15/25

RBC Capital Reaffirms Their Hold Rating on Cochlear (CHEOF)

Marcus Curley

UBS

$212.88→$229.25

Buy

15.03%

Upside

Reiterated

08/15/25

UBS Sticks to Their Buy Rating for Cochlear (CHEOF)

Unknown Analyst

Macquarie

Not Ranked

Macquarie

$177.9→$177.18

Hold

-11.10%

Downside

Reiterated

07/16/25

Cochlear (CHEOF) Receives a Hold from Macquarie

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$186.68→$193.23

Hold

-3.05%

Downside

Reiterated

07/09/25

Cochlear (CHEOF) Receives a Hold from Ord Minnett

Davinthra Thillainathan

Goldman Sachs

―

Hold

―

Reiterated

06/14/25

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (NASDAQ: TNDM) and Cochlear (Other OTC: CHEOF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cochlear

1 Month

xxx

Success Rate

4/7 ratings generated profit

Average Return

-0.41%

upgraded a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of -0.41% per trade.

3 Months

xxx

Success Rate

4/7 ratings generated profit

Average Return

+0.60%

upgraded a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +0.60% per trade.

1 Year

Mathieu ChevrierCiti

Success Rate

5/6 ratings generated profit

Average Return

+7.52%

reiterated a buy rating 22 days ago

Copying Mathieu Chevrier's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +7.52% per trade.

2 Years

xxx

Success Rate

5/6 ratings generated profit

Average Return

+7.52%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +7.52% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CHEOF Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CHEOF has received 6 Buy Ratings, 11 Hold Ratings, and 2 Sell Ratings. CHEOF average Analyst price target in the past 3 months is 207.10.

Each month's total comprises the sum of three months' worth of ratings.

CHEOF Financial Forecast

CHEOF Earnings Forecast

Next quarter’s earnings estimate for CHEOF is $2.05 with a range of $1.92 to $2.16. The previous quarter’s EPS was $1.84. CHEOF beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year CHEOF has Outperformed its overall industry.

CHEOF Sales Forecast

Next quarter’s sales forecast for CHEOF is $800.05M with a range of $793.73M to $814.80M. The previous quarter’s sales results were $769.34M. CHEOF beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.23% of the time in the same period. In the last calendar year CHEOF has Preformed in-line its overall industry.

CHEOF Stock Forecast FAQ

What is CHEOF’s average 12-month price target, according to analysts?

Based on analyst ratings, Cochlear Limited’s 12-month average price target is 207.10.

What is CHEOF’s upside potential, based on the analysts’ average price target?

Cochlear Limited has 3.91% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CHEOF a Buy, Sell or Hold?

Cochlear Limited has a consensus rating of Hold which is based on 4 buy ratings, 6 hold ratings and 2 sell ratings.

What is Cochlear Limited’s price target?

The average price target for Cochlear Limited is 207.10. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $233.18 ,the lowest forecast is $182.42. The average price target represents 3.91% Increase from the current price of $199.3.

What do analysts say about Cochlear Limited?

Cochlear Limited’s analyst rating consensus is a Hold. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of CHEOF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Cochlear (CHEOF) Stock Forecast & Price Target

CHEOF Analyst Ratings

CHEOF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cochlear

CHEOF Analyst Recommendation Trends

CHEOF Financial Forecast

CHEOF Earnings Forecast

CHEOF Sales Forecast

CHEOF Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts